Bristol Myers Squibb is deeply committed to unlocking the potential of CAR T cell therapy in autoimmune disease
CD19 CAR T cell therapy is in development across a variety of rheumatological and neuroinflammatory autoimmune diseases.
BMS CAR T clinical trials are currently enrolling patients with autoimmune diseases.1-4
Phase 2 clinical trial
Phase 1 clinical trials
Find a trial and study site for a patient today
CAR=chimeric antigen receptor.
References:
- Clinicaltrials.gov. NCT05869955. Accessed October 8, 2025.
- Data on file. REF-00068-466. Princeton, NJ: Bristol-Myers Squibb Company; 2024.
- Clinicaltrials.gov. NCT06220201. Accessed March 13, 2025.
- Clinicaltrials.gov. NCT07015983. Accessed June 11, 2025.